Literature DB >> 31677989

Pregnancy and Systemic Lupus Erythematosus.

Michelle Petri1.   

Abstract

As SLE onset is often in young adulthood, pregnancy is common and is usually successful. Pregnancy, though, is considered high-risk due to a combination of maternal (lupus flare, diabetes, pre-eclampsia) and fetal (miscarriage, intrauterine fetal demise, preterm birth, intrauterine growth restriction, congenital heart block) risks. Pregnancy should be planned for a time of good control of SLE (on allowable medications). The antimalarial hydroxychloroquine should be continued. The only permitted immunosuppressive drugs are azathioprine and tacrolimus. Of the antiphospholipid antibodies, only the lupus anticoagulant has been associated with adverse pregnancy outcomes in the largest prospective multicenter study, Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus (PROMISSE). Management of antiphospholipid syndrome in pregnancy is low molecular weight heparin and aspirin, although only 75% of pregnancies are successful.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Antiphospholipid antibodies; Lupus anticoagulant; Lupus nephritis; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2019        PMID: 31677989     DOI: 10.1016/j.bpobgyn.2019.09.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  7 in total

1.  Predictors of refractory risk in systemic lupus erythematosus-related thrombocytopenia: a dual-centre retrospective study.

Authors:  Kaisheng Su; Hao Cheng; Zhifang Jia; Yi Yuan; Huidan Yang; Qi Gao; Zhenyu Jiang; Hongyan Wen; Jing Jiang
Journal:  Lupus Sci Med       Date:  2022-05

Review 2.  Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review.

Authors:  Jaume Alijotas-Reig; Enrique Esteve-Valverde; Ariadna Anunciación-Llunell; Joana Marques-Soares; Josep Pardos-Gea; Francesc Miró-Mur
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

3.  Use of Prescribed Drugs to Treat Chronic Diseases during Pregnancy in Outpatient Care in Switzerland between 2014 and 2018: Descriptive Analysis of Swiss Health Care Claims Data.

Authors:  Eva Gerbier; Sereina M Graber; Marlene Rauch; Carole A Marxer; Christoph R Meier; David Baud; Ursula Winterfeld; Eva Blozik; Daniel Surbek; Julia Spoendlin; Alice Panchaud
Journal:  Int J Environ Res Public Health       Date:  2022-01-27       Impact factor: 3.390

Review 4.  Systemic Lupus Erythematosus Management in Pregnancy.

Authors:  Kathryn H Dao; Bonnie L Bermas
Journal:  Int J Womens Health       Date:  2022-02-15

Review 5.  Estrogen, the Peripheral Immune System and Major Depression - A Reproductive Lifespan Perspective.

Authors:  Elizabeth B Engler-Chiurazzi; Wesley H Chastain; Kailen K Citron; Lillian E Lambert; Divya N Kikkeri; Sharhana S Shrestha
Journal:  Front Behav Neurosci       Date:  2022-04-15       Impact factor: 3.617

Review 6.  Gender-Diverse Inclusion in Immunological Research: Benefits to Science and Health.

Authors:  Hannah Peckham; Kate Webb; Elizabeth C Rosser; Gary Butler; Coziana Ciurtin
Journal:  Front Med (Lausanne)       Date:  2022-07-14

7.  Cardiac Tamponade as Initial Presentation of Systemic Lupus Erythematosus in Third-Trimester Pregnancy.

Authors:  Patrick A Yousif; Shwetha Sudhakar; Charles Malemud; David E Blumenthal
Journal:  Am J Case Rep       Date:  2022-07-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.